Cefoperazone/Sulbactam In The Treatment Of Serious Intra-Abdominal And Hepatobiliary Infections.

Cefoperazone/Sulbactam In The Treatment Of Serious Intra-Abdominal And Hepatobiliary Infections In Slovakia. An Open, Prospective, Non-Comparative Study.

Status

Withdrawn

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00463762

Enrollment

Registered

2007-04-20

Start date

2007-05-31

Completion date

Unknown

Last updated

2011-04-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Abscess, Intra-Abdominal, Appendicitis, Cholecystitis, Peritonitis, Wound Infections

Brief summary

The primary objective is to collect data on treatment outcomes (clinical and microbiological cure), safety and tolerability of treatment with cefoperazone/sulbactam in patients with serious intra-abdominal and hepatobiliary infections in Slovakia.

Interventions

DRUGCP-75385-02 Cefoperazone/sulbactam

Study design

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Male or female patient of age 18 years or older. * Patient with intraabdominal/hepatobiliary infection.?

Exclusion criteria

* Patients with known hypersensitivity to penicillins, cephalosporins, cefoperazone or to sulbactam.

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026